Myélome

TITRE	(EN) Elranatamab post trial access: an open-label, single-arm study for participants with multiple myeloma continuing from Pfizer-sponsored Elranatamab clinical studies
PROTOCOLE ID	MagnetisMM15
CLINICAL TRIAL.gov ID	NCT06057402
TYPE(S) DE CANCER	Myélome
PHASE	Autres
TYPE D'ÉTUDE	Clinique
INSTITUTION	CUSM 1001 boul. Décarie
VILLE	Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E)	Chaim Shustik Michael Sebag
COORDONATEUR(RICE)	Nancy Renouf nancy.renouf@muhc.mcgill.ca 514-934-1934 poste 35718
STATUT	Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ	(EN) Participants must agree to follow the reproductive criteria as outlined in the protocol Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator).
CRITÈRES D'EXCLUSION	(EN) Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.